Dr Ricardo Fernandes is a Group Leader at the CAMS Oxford Institute and Nuffield Department of Medicine at the University of Oxford. He holds a PhD from Oxford, where he worked with Simon Davis to elucidate the mechanism of TCR triggering. Later, he moved to Stanford, where he developed innovative bispecific proteins that utilize endogenous membrane phosphatases to inhibit signalling by surface receptors found in T cells. The Fernandes’ Lab focuses on elucidating the functional and structural aspects of immune receptor signalling and identifying novel therapeutic strategies for modulating T cell function in the context of autoimmunity and cancer.